# Axogen, Inc.: overview

AXGN · Nasdaq · CIK 805928 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/axgn.md) · [Financials](/companies/axgn/financials.md) · [Filings](/companies/axgn/filings.md) · [Insiders](/companies/axgn/insiders.md)

Latest reported revenue: [$69.7m](/filings/0000805928-26-000094.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:Revenues, accession 0000805928-26-000094).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [48.6](/filings/0000805928-25-000130.md) | [49.4 d](/filings/0000805928-26-000031.md) | [48.6](/filings/0000805928-26-000053.md) | [56.7](/filings/0000805928-26-000094.md) | [60.1](/filings/0000805928-25-000130.md) | [59.9 d](/filings/0000805928-26-000031.md) | [61.5](/filings/0000805928-26-000053.md) | [69.7](/filings/0000805928-26-000094.md) |
| Gross margin | % | [74.9%](/filings/0000805928-25-000130.md) | [76.1% d](/filings/0000805928-26-000031.md) | [71.9%](/filings/0000805928-26-000053.md) | [74.2%](/filings/0000805928-26-000094.md) | [76.6%](/filings/0000805928-25-000130.md) | [74.1% d](/filings/0000805928-26-000031.md) | [75.2%](/filings/0000805928-26-000053.md) | [72.7%](/filings/0000805928-26-000094.md) |
| Operating margin | % | [(0.6%)](/filings/0000805928-25-000130.md) | [4.1% d](/filings/0000805928-26-000031.md) | [(3.4%)](/filings/0000805928-26-000053.md) | [3.0%](/filings/0000805928-26-000094.md) | [3.2%](/filings/0000805928-25-000130.md) | [(16.3%) d](/filings/0000805928-26-000031.md) | [(4.6%)](/filings/0000805928-26-000053.md) | [(3.1%)](/filings/0000805928-26-000094.md) |
| Net margin | % | [(3.8%)](/filings/0000805928-25-000130.md) | [0.9% d](/filings/0000805928-26-000031.md) | [(7.9%)](/filings/0000805928-26-000053.md) | [1.0%](/filings/0000805928-26-000094.md) | [1.2%](/filings/0000805928-25-000130.md) | [(22.0%) d](/filings/0000805928-26-000031.md) | [(31.9%)](/filings/0000805928-26-000053.md) | [(2.2%)](/filings/0000805928-26-000094.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000805928-25-000130.md) | not reported | [(0.08)](/filings/0000805928-26-000053.md) | [0.01](/filings/0000805928-26-000094.md) | [0.01](/filings/0000805928-25-000130.md) | not reported | [(0.38)](/filings/0000805928-26-000053.md) | [(0.03)](/filings/0000805928-26-000094.md) |
| Free cash flow | $m | [3.3 d](/filings/0000805928-25-000130.md) | [8.1 d](/filings/0000805928-26-000031.md) | [(13.4)](/filings/0000805928-26-000053.md) | [7.0 d](/filings/0000805928-26-000094.md) | [1.7 d](/filings/0000805928-25-000130.md) | [1.8 d](/filings/0000805928-26-000031.md) | [(1.2)](/filings/0000805928-26-000053.md) | [6.3 d](/filings/0000805928-26-000094.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [127](/filings/0000805928-24-000028.md) | [139](/filings/0000805928-25-000017.md) | [159](/filings/0000805928-26-000031.md) | [187](/filings/0000805928-26-000031.md) | [225](/filings/0000805928-26-000031.md) |
| Gross margin | % | [82.0%](/filings/0000805928-24-000028.md) | [78.5%](/filings/0000805928-25-000017.md) | [76.6%](/filings/0000805928-26-000031.md) | [75.8%](/filings/0000805928-26-000031.md) | [74.3%](/filings/0000805928-26-000031.md) |
| Operating margin | % | [(20.0%)](/filings/0000805928-24-000028.md) | [(21.4%)](/filings/0000805928-25-000017.md) | [(13.5%)](/filings/0000805928-26-000031.md) | [(1.8%)](/filings/0000805928-26-000031.md) | [(3.5%)](/filings/0000805928-26-000031.md) |
| Net margin | % | [(21.2%)](/filings/0000805928-24-000028.md) | [(20.9%)](/filings/0000805928-25-000017.md) | [(13.7%)](/filings/0000805928-26-000031.md) | [(5.3%)](/filings/0000805928-26-000031.md) | [(7.0%)](/filings/0000805928-26-000031.md) |
| Diluted EPS | $ per share | [(0.65)](/filings/0000805928-24-000028.md) | [(0.69)](/filings/0000805928-25-000017.md) | [(0.51)](/filings/0000805928-26-000031.md) | [(0.23)](/filings/0000805928-26-000031.md) | [(0.34)](/filings/0000805928-26-000031.md) |
| Free cash flow | $m | [(41.2)](/filings/0000805928-24-000028.md) | [(36.1)](/filings/0000805928-25-000017.md) | [(19.6)](/filings/0000805928-26-000031.md) | [1.4](/filings/0000805928-26-000031.md) | [(2.9)](/filings/0000805928-26-000031.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/axgn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $204.1m | 4,419,208 |  | Added +548,357 |
| [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $126.9m | 2,748,361 |  | Reduced −1,254,407 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $126.9m | 2,747,924 |  | Reduced −375,058 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $104.3m | 2,257,948 |  | Reduced −33,615 |
| [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $69.3m | 1,500,822 |  | Unchanged |
| [Artemis Investment Management LLP](/funds/1535385.md) | 2026-06-30 | $64.5m | 1,396,792 |  | Added +1,046,904 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $64.3m | 1,391,654 |  | Added +427,089 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $63.5m | 1,375,240 |  | Added +155,099 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $62.9m | 1,360,831 |  | Added +1,115,777 |
| [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $59.9m | 1,295,949 |  | Reduced −561,401 |

## Recent filings

[All 1,230 filings](/companies/axgn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-01 | 17:25 ET | [8-K](/filings/0000805928-26-000104.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000805928-26-000104 |
| 2026-09-10 | 16:55 ET | [8-K/A](/filings/0001628280-26-061393.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-061393 |
| 2026-09-10 | 06:02 ET | [8-K](/filings/0001628280-26-061208.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-061208 |
| 2026-07-29 | 16:13 ET | [10-Q](/filings/0000805928-26-000094.md) | Quarterly report, period 2026-06-30 | 0000805928-26-000094 |
| 2026-07-29 | 07:11 ET | [8-K](/filings/0000805928-26-000091.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000805928-26-000091 |
| 2026-06-23 | 16:39 ET | [8-K](/filings/0000805928-26-000081.md) | 5.07 Shareholder vote results | 0000805928-26-000081 |
| 2026-04-29 | 16:05 ET | [DEF 14A](/filings/0000805928-26-000057.md) | Proxy statement, period 2025-12-31 | 0000805928-26-000057 |
| 2026-04-28 | 16:04 ET | [10-Q](/filings/0000805928-26-000053.md) | Quarterly report, period 2026-03-31 | 0000805928-26-000053 |
| 2026-04-28 | 07:02 ET | [8-K](/filings/0000805928-26-000051.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000805928-26-000051 |
| 2026-02-24 | 16:24 ET | [10-K](/filings/0000805928-26-000031.md) | Annual report, period 2025-12-31 | 0000805928-26-000031 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000805928-26-000031.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ed461010-0677-4a50-8471-ad9261790238)

## About the filer

- CIK: 805928
- Tickers: AXGN
- Exchange: Nasdaq
- SIC code: 3845 Electromedical & Electrotherapeutic Apparatus
- State of incorporation: MN
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 07:05 ET. No prices; not investment advice.